Directory of funded grants

Filter by

720 results found

ShARP: Screenable assays for RNA-binding proteins involved in brain disorders and diseases

  • Grant Type

    Platform grants

  • Area of research

    Neurotechnology

  • Disease Area

    Other

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2016

  • Total Grant Amount

    $1,477,008

  • Health Canada Contribution

    $738,504

Project Overview

Brain disorders such as autism, major depressive disorder and Alzheimer’s disease are among the greatest medical challenges of our era. Many drugs targeting the central nervous system (CNS) have been developed to modulate G protein-coupled receptors, ion channels or transporters with mitigated success. There remains a shortage of disease-relevant targets…

A Patient-Derived hiPSC Neuronal Platform for Drug Discovery in Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  • Grant Type

    Platform grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Parkinson'sALS

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Québec

  • Start Date

    2016

  • Total Grant Amount

    $1,500,000

  • Health Canada Contribution

    $750,000

Project Overview

Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) are two of the most common and devastating neurodegenerative diseases, affecting more than 2% of the population over the age of 65. However, a major hindrance in developing therapies for disorders of the brain has been limited access to human neurons from…

Non Invasive Identification of Aβ Plaques in Human Retina for the Diagnosis of Alzheimer’s Disease

  • Grant Type

    Platform grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Québec

  • Start Date

    2015

  • Total Grant Amount

    $1,500,000

  • Health Canada Contribution

    $639,105

Project Overview

Currently, AD diagnosis can only be confirmed post-mortem by observing two AD hallmarks in the brain, β-amyloid (Aβ) plaques and tau strands. Diagnosing AD earlier in its course could dramatically transform the design of clinical trials to test new treatments. A team of researchers led by Dr. Jean-Paul Soucy of…

Solid phase microextraction-based integrated platform for untargeted and targeted in vivo brain studies

  • Grant Type

    Platform grants

  • Area of research

    Neurotechnology

  • Disease Area

    Other

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $995,427

  • Health Canada Contribution

    $386,818

Project Overview

This project proposes to integrate the low-invasive, non-lethal in vivo sampling/sample preparation SPME approach with MS detection to obtain the full profile of brain metabolome and lipidome, the quantification of drugs and monitoring of their metabolism, selective extraction of target compounds (drugs or selected endogenous metabolite), as well as high…

Drug Delivery across the Human Blood-Brain Barrier

  • Grant Type

    Platform grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $1,496,800

  • Health Canada Contribution

    $637,505

Project Overview

Toxic amyloid proteins are known to be a significant contributing factor in the development of Alzheimer’s disease. Abnormal clusters of protein fragments build up between nerve cells in the brainleading to impaired memory. The most important therapies in development currently are biologics, antibodies and peptides that bind and neutralize toxic…